A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease [0.03%]
一种针对高危骨髓增生异常综合征和急性髓系白血病（包括TP53突变型）的CCRL2抗体药物偶联物PBD二聚体ADC
Nour Sabiha Naji,Taha Soueidatt Ahmedna,Xinghan Zeng et al.
Nour Sabiha Naji et al.
Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) with high-risk features including TP53 mutations have poor outcomes due to lack of effective therapies. The atypical chemokine surface receptor C-C motif chemokine re...
Wolfgang Miesbach,Roland Herzog
Wolfgang Miesbach
Molly Y Mollica
Molly Y Mollica
Gabriela Llaurador Caraballo,David Steffin
Gabriela Llaurador Caraballo
Joshua M L Casan,Carrie Van Der Weyden
Joshua M L Casan
Stacy E Croteau
Stacy E Croteau
Clofarabine for relapsed/refractory Langerhans cell (LC) and non-LC histiocytosis [0.03%]
克拉拉滨治疗复发/难治性朗格汉斯细胞（LC）和非LC组织细胞增生症的效果和安全性评估
Barbara A Degar,Oussama Abla,Patrick K Campbell et al.
Barbara A Degar et al.
Langerhans cell histiocytosis (LCH) and non-LC histiocytosis are rare neoplastic diseases with variable behavior. Although chemotherapy is effective in many patients, disease recurrence is common, and some patients respond poorly to treatme...
Christian Brieghel,Mikkel Werling,Peter de Nully Brown et al.
Christian Brieghel et al.
HNRNPU Mutations Redirect Cell Cycle Control to E2F in MYC-Driven Lymphomas [0.03%]
MYC驱动的淋巴瘤中HNRNPU突变使细胞周期调控偏离CBP转向E2F
Quratulain Qureshi,Krysta Mila Coyle,Callum Brown et al.
Quratulain Qureshi et al.
hnRNPU is a ubiquitously expressed, pleiotropic DNA and RNA binding protein involved in RNA metabolism. Heterozygous HNRNPU nonsense mutations have been observed in a variety of B-cell lymphomas, but the functional consequence of these muta...
Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma [0.03%]
基线FDG PET/CT影像组学参数联合预测原发纵隔B细胞淋巴瘤的预后价值
Pierre Decazes,Cedric Rossi,Pierre Sesques et al.
Pierre Decazes et al.
Primary mediastinal B-cell lymphoma (PMBL) is an uncommon aggressive lymphoma with generally favorable outcomes; however, 15-20% of patients develop refractory disease. Reliable baseline prognostic biomarkers remain lacking. We evaluated th...